To view AHRP news and infomails from 2006, please visit our new site. Infomails Subscribe to AHRP’s infomails At FDA, Graham is still the whistle-blower Loss of Trust: Big Drug Makers See Sales Decline With Their Image War hero’s death in clinical trial follows years of FDA neglect European perspective:…
Natrecor found to worsen kidney function, hasten death – NYT Tue, 17 May 2005 Natrecor, a drug approved by the FDA for treating patients with heart failure, is being widely prescribed off label for unapproved uses. The drug is prescribed for so-called “tune-ups” in outpatient clinics – although that use…
FDA Scientist Won’t Present New Pain Drug Data – FDA to Create Independent Drug Safety Board Tue, 15 Feb 2005 A culture of intimidation prevents FDA safety officers from disclosing important safety information about widely marketed drugs. Reuters reports: “Criticism of how the FDA monitors the after-market safety of drugs…
Selling Sickness: Pharma Industry Turning Us All Into Patients Mon, 12 Sep 2005 Related Link: Selling Sickness Prologue Selling Sickness: How the World’s Pharmaceutical Companies Are Turning Us All Into Patients, by Ray Moynihan, an international health journalist, and Alan Cassels, a pharmaceutical policy researcher, is likely to become a…
Intimidation, Politics and Drug Industry Cripple U.S. Medicine – FDA Permits Dr. David Graham to publish Vioxx Report Wed, 5 Jan 2005 FDA officials could not maintain their iron grip in an effort to suppress evidence of far reaching lethal effects of Vioxx when their actions were in full public…
Daniel Troy Legacy: Public Virtually Defenseless against Unsafe Drugs Thu, 18 Nov 2004 The Associated Press reports that at a Congressional hearing today, Dr. David Graham a drug safety expert at the FDA told the Senate Finance Committee that the public is “virtually defenseless” if another medication such as Vioxx…
AHRP Speaks Out AHRP Press Briefing 9/14/04: Antidepressants & suicide-related risks for children Open Letter to NIMH re Prozac & Concealed Suicide Attempts Open Letter to Officials at NIMH AHRP Briefing 2/2/04: Scientists present suicide evidence Conflicts of Interest policy – New York Times Phase I Drug Trials Used Foster…
Pharma Ethics: Merck CEO Resigns – Vioxx deceptive Marketing / AIDS drug experiments Foster Kids Fri, 06 May 2005 Merck CEO Raymond Gilmartin, resigned abruptly after he spent 11 years at the helm. The Washington Post reports the resignation “came on a day when Merck was sharply criticized in a…
Forbes: Judgment Day for the FDA, Pfizer Wed, 9 Feb 2005 On Feb. 16-18 COX-2 Inhibitor Safety Issues will be the focus of an FDA Advisory Committee and (simultaneously) the European Medicines Agency (EMA). The entire drug industry will be watching with bated breath. Which causal explanation will be offered…
Suicide Rate Unchanged in 10 Years–JAMA / AMA Considers Stand Against Warning Labels on Antidepressants Thu, 9 Jun 2005 A major report in the Journal of the American Medical Association shatters all claims about the effectiveness of antidepressants as a treatment for the prevention of suicide. A comparison of the…
Eli Lilly Prozac Documents: What do They Reveal? Thu, 27 Jan 2005 A report in the BMJ (formerly the British Medical Journal) that relied on internal Eli Lilly documents to challenge Lilly’s claims about the safety of Prozac has stirred a prickly hornet’s nest. [1] The documents show, among other…
FDA Strong Drug Ties-Less Monitoring – UK MHRA Mon, 6 Dec 2004 A front page article in The New York Times provides a historical perspective to the shift in FDA’s focus (in 1992) from watchdog safeguarding the public against hazardous drugs, food and medical devices, to its current role as…
